Tenaya Therapeutics, Inc. (TNYA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol TNYA
- Company Tenaya Therapeutics, Inc.
- Price $1.16
- Changes Percentage 22.51
- Change 0.2131
- Day Low $0.94
- Day High $1.16
- Year High $4.01
- Year Low $0.36
- Market Cap $109,014,646
- Price Avg 50 EMA (D) $0.66
- Price Avg 200 EMA (D) $1.15
- Exchange NASDAQ
- Volume 1,229,574
- Average Volume 2,445,513
- Open $0.96
- Previous Close $0.95
- EPS -0.94
- PE -0.71
- Earnings Announcement 2025-11-05 05:00:00
- Shares Outstanding $162,976,000
Company brief: TENAYA THERAPEUTICS, INC. (TNYA )
- Healthcare
- Biotechnology
- Mr. Faraz Ali M.B.A.
- https://www.tenayatherapeutics.com
- US
- N/A
- 07-30-2021
- US87990A1060
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.